Literature DB >> 16699016

Characterization of a permissive epitope insertion site in adenovirus hexon.

Michael J McConnell1, Xavier Danthinne, Michael J Imperiale.   

Abstract

A robust immune response is generated against components of the adenovirus capsid. In particular, a potent and long-lived humoral response is elicited against the hexon protein. This is due to the efficient presentation of adenovirus capsid proteins to CD4+ T cells by antigen-presenting cells, in addition to the highly repetitive structure of the adenovirus capsids, which can efficiently stimulate B-cell proliferation. In the present study, we take advantage of this immune response by inserting epitopes against which an antibody response is desired into the adenovirus hexon. We use a B-cell epitope from Bacillus anthracis protective antigen (PA) as a model antigen to characterize hypervariable region 5 (HVR5) of hexon as a site for peptide insertion. We demonstrate that HVR5 can accommodate a peptide of up to 36 amino acids without adversely affecting virus infectivity, growth, or stability. Viruses containing chimeric hexons elicited antibodies against PA in mice, with total immunoglobulin G (IgG) titers reaching approximately 1 x 10(3) after two injections. The antibody response contained both IgG1 and IgG2a subtypes, suggesting that Th1 and Th2 immunity had been stimulated. Coinjection of wild-type adenovirus and a synthetic peptide from PA produced no detectable antibodies, indicating that incorporation of the epitope into the capsid was crucial for immune stimulation. Together, these results indicate that the adenovirus capsid is an efficient vehicle for presenting B-cell epitopes to the immune system, making this a useful approach for the design of epitope-based vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16699016      PMCID: PMC1472126          DOI: 10.1128/JVI.00256-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  75 in total

1.  Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions.

Authors:  Ronald G Crystal; Ben-Gary Harvey; Juan P Wisnivesky; Kelley A O'Donoghue; Karen W Chu; Jaman Maroni; Jolene C Muscat; Allison L Pippo; Connie E Wright; Robert J Kaner; Philip L Leopold; Paul D Kessler; Henrik S Rasmussen; Todd K Rosengart; Charleen Hollmann
Journal:  Hum Gene Ther       Date:  2002-01-01       Impact factor: 5.695

Review 2.  Lipopeptide vaccines--yesterday, today, and tomorrow.

Authors:  Lbachir BenMohamed; Steven L Wechsler; Anthony B Nesburn
Journal:  Lancet Infect Dis       Date:  2002-07       Impact factor: 25.071

3.  Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus.

Authors:  Myrna C Bonaldo; Richard C Garratt; Philippe S Caufour; Marcos S Freire; Mauricio M Rodrigues; Ruth S Nussenzweig; Ricardo Galler
Journal:  J Mol Biol       Date:  2002-01-25       Impact factor: 5.469

4.  A rapid and easy method for production and selection of recombinant adenovirus genomes.

Authors:  Laurence Renaut; Claudine Bernard; Jean Claude D'Halluin
Journal:  J Virol Methods       Date:  2002-02       Impact factor: 2.014

5.  Import of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and histone H1.

Authors:  L C Trotman; N Mosberger; M Fornerod; R P Stidwill; U F Greber
Journal:  Nat Cell Biol       Date:  2001-12       Impact factor: 28.824

Review 6.  Ins and outs of clinical trials with peptide-based vaccines.

Authors:  Rachel B Salit; W Martin Kast; Markwin P Velders
Journal:  Front Biosci       Date:  2002-05-01

7.  Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites.

Authors:  James G Kublin; Mark H Lowitt; Robert G Hamilton; Giane A Oliveira; Elizabeth H Nardin; Ruth S Nussenzweig; Barbara J Schmeckpeper; Carter L Diggs; Sacared A Bodison; Robert Edelman
Journal:  Vaccine       Date:  2002-03-15       Impact factor: 3.641

8.  Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity.

Authors:  Jennifer A Maynard; Catharina B M Maassen; Stephen H Leppla; Kathleen Brasky; Jean L Patterson; Brent L Iverson; George Georgiou
Journal:  Nat Biotechnol       Date:  2002-06       Impact factor: 54.908

9.  Requirement of the adenovirus IVa2 protein for virus assembly.

Authors:  Wei Zhang; Michael J Imperiale
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

10.  Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines.

Authors:  Weiguang Zeng; Souravi Ghosh; Yuk Fai Lau; Lorena E Brown; David C Jackson
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

View more
  29 in total

Review 1.  Progress on adenovirus-vectored universal influenza vaccines.

Authors:  Kui Xiang; Guan Ying; Zhou Yan; Yan Shanshan; Zhang Lei; Li Hongjun; Sun Maosheng
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii.

Authors:  Michael J McConnell; Juan Domínguez-Herrera; Younes Smani; Rafael López-Rojas; Fernando Docobo-Pérez; Jerónimo Pachón
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

Review 3.  Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.

Authors:  Qiana L Matthews
Journal:  Mol Pharm       Date:  2010-12-01       Impact factor: 4.939

4.  Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection.

Authors:  Wibke Bayer; Matthias Tenbusch; Ruth Lietz; Lena Johrden; Simone Schimmer; Klaus Uberla; Ulf Dittmer; Oliver Wildner
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

5.  Ternary complex formation on the adenovirus packaging sequence by the IVa2 and L4 22-kilodalton proteins.

Authors:  Sean G Ewing; Serena A Byrd; Joan B Christensen; Ryan E Tyler; Michael J Imperiale
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

6.  Her2-specific multivalent adapters confer designed tropism to adenovirus for gene targeting.

Authors:  Birgit Dreier; Galina Mikheeva; Natalya Belousova; Petra Parizek; Edgar Boczek; Ilian Jelesarov; Patrik Forrer; Andreas Plückthun; Victor Krasnykh
Journal:  J Mol Biol       Date:  2010-11-05       Impact factor: 5.469

7.  Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice.

Authors:  Takayuki Shiratsuchi; Urvashi Rai; Anja Krause; Stefan Worgall; Moriya Tsuji
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

8.  Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine.

Authors:  Jonathan B Rosenberg; Bishnu P De; Martin J Hicks; Kim D Janda; Stephen M Kaminsky; Stefan Worgall; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2013-06       Impact factor: 5.695

9.  The epitope of the VP1 protein of porcine parvovirus.

Authors:  Hong-ling Xie; Zhao Wang; Shang-jin Cui; Chao-fan Zhang; Yu-dong Cui
Journal:  Virol J       Date:  2010-07-16       Impact factor: 4.099

Review 10.  Prospects for oral replicating adenovirus-vectored vaccines.

Authors:  Cailin Deal; Andrew Pekosz; Gary Ketner
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.